strong>Celltrion Healthcare Co. Ltd., of Incheon, South Korea, notified the FDA that Janssen Biotech Inc., of Horsham, Pa., part of Johnson & Johnson, has filed a patent infringement complaint against its Remsima, a proposed biosimilar to Janssen's Remicade (infliximab).